Terms: = Breast cancer AND FOXP3, AIID, DIETER, IPEX, JM2, PIDX, XPID AND Treatment
153 results:
1. pDNA-tachyplesin treatment stimulates the immune system and increases the probability of apoptosis in MC4-L2 tumor cells.
Mahmoudi-Filabadi F; Doosti A
Amino Acids; 2024 May; 56(1):34. PubMed ID: 38691208
[TBL] [Abstract] [Full Text] [Related]
2. Multiplexed high-throughput immune cell imaging in patients with high-risk triple negative early breast cancer: Analysis from the International breast cancer Study Group (IBCSG) Trial 22-00.
Rusakiewicz S; Tyekucheva S; Tissot-Renaud S; Chaba K; Imbimbo M; Benedetti F; Kammler R; Hornfeld J; Munzone E; Gianni L; Thurlimann B; Láng I; Pruneri G; Gray KP; Regan MR; Loi S; Colleoni M; Viale G; Kandalaft L; Coukos G; Curigliano G
Eur J Cancer; 2024 Mar; 200():113535. PubMed ID: 38309015
[TBL] [Abstract] [Full Text] [Related]
3. The relationship between high ratios of CD4/foxp3 and CD8/CD163 and the improved survivability of metastatic triple-negative breast cancer patients: a multicenter cohort study.
Tenggara JB; Rachman A; Prihartono J; Rachmadi L; Panigoro SS; Heriyanto DS; Sutandyo N; Nasution IR; Rahadiati FB; Steven R; Betsy R; Juanputra S; Sudoyo AW
BMC Res Notes; 2024 Feb; 17(1):44. PubMed ID: 38308298
[TBL] [Abstract] [Full Text] [Related]
4. Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer-Immun-HER trial (GOIRC-01-2016).
Pellegrino B; Tommasi C; Serra O; Gori S; Cretella E; Ambroggi M; Frassoldati A; Bisagni G; Casarini C; Bria E; Carbognin L; Fiorio E; Mura A; Zamagni C; Gianni L; Zambelli A; Montemurro F; Tognetto M; Todeschini R; Missale G; Campanini N; Silini EM; Maglietta G; Musolino A
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38016718
[TBL] [Abstract] [Full Text] [Related]
5. Neutralizing tumor-related inflammation and reprogramming of cancer-associated fibroblasts by Curcumin in breast cancer therapy.
Jalilian E; Abolhasani-Zadeh F; Afgar A; Samoudi A; Zeinalynezhad H; Langroudi L
Sci Rep; 2023 Nov; 13(1):20770. PubMed ID: 38008819
[TBL] [Abstract] [Full Text] [Related]
6. Caffeine-folic acid-loaded-chitosan nanoparticles combined with methotrexate as a novel HepG2 immunotherapy targeting adenosine A2A receptor downstream cascade.
Hamed A; Ghareeb D; Mohamed TM; Hamed M; Nofal MS; Gaber M
BMC Complement Med Ther; 2023 Oct; 23(1):384. PubMed ID: 37891562
[TBL] [Abstract] [Full Text] [Related]
7. Targeting foxp3 Tumor-Intrinsic Effects Using Adenoviral Vectors in Experimental breast cancer.
Nicola Candia AJ; Garcia Fallit M; Peña Agudelo JA; Pérez Küper M; Gonzalez N; Moreno Ayala MA; De Simone E; Giampaoli C; Casares N; Seilicovich A; Lasarte JJ; Zanetti FA; Candolfi M
Viruses; 2023 Aug; 15(9):. PubMed ID: 37766222
[TBL] [Abstract] [Full Text] [Related]
8. pH-Responsive Zinc Ion Regulating Immunomodulatory Nanoparticles for Effective cancer Immunotherapy.
Lim B; Kim KS; Na K
Biomacromolecules; 2023 Sep; 24(9):4263-4273. PubMed ID: 37616157
[TBL] [Abstract] [Full Text] [Related]
9. The immune microenvironment characterisation and dynamics in hormone receptor-positive breast cancer before and after neoadjuvant endocrine therapy.
Oner G; Broeckx G; Van Berckelaer C; Zwaenepoel K; Altintas S; Canturk Z; Tjalma W; Berneman Z; Peeters M; Pauwels P; van Dam PA
Cancer Med; 2023 Sep; 12(17):17901-17913. PubMed ID: 37553911
[TBL] [Abstract] [Full Text] [Related]
10. Tumor infiltrating lymphocytes and neutrophil-to-lymphocyte ratio in relation to pathological complete remission to neoadjuvant therapy and prognosis in triple negative breast cancer.
Zhao M; Xing H; He J; Wang X; Liu Y
Pathol Res Pract; 2023 Aug; 248():154687. PubMed ID: 37478522
[TBL] [Abstract] [Full Text] [Related]
11. Ponatinib delays the growth of solid tumours by remodelling immunosuppressive tumour microenvironment through the inhibition of induced PD-L1 expression.
Barnwal A; Tamang R; Sanjeev Das ; Bhattacharyya J
Br J Cancer; 2023 Oct; 129(6):1007-1021. PubMed ID: 37400678
[TBL] [Abstract] [Full Text] [Related]
12. Nivolumab plus chemoradiotherapy in locally-advanced cervical cancer: the NICOL phase 1 trial.
Rodrigues M; Vanoni G; Loap P; Dubot C; Timperi E; Minsat M; Bazire L; Durdux C; Fourchotte V; Laas E; Pouget N; Castel-Ajgal Z; Marret G; Lesage L; Meseure D; Vincent-Salomon A; Lecompte L; Servant N; Vacher S; Bieche I; Malhaire C; Huchet V; Champion L; Kamal M; Amigorena S; Lantz O; Chevrier M; Romano E
Nat Commun; 2023 Jun; 14(1):3698. PubMed ID: 37349318
[TBL] [Abstract] [Full Text] [Related]
13. βhCG mediates immune suppression through upregulation of CD11b
Varghese GR; Patra D; Jaikumar VS; Rajan A; Latha NR; Srinivas P
Immunology; 2023 Oct; 170(2):270-285. PubMed ID: 37340549
[TBL] [Abstract] [Full Text] [Related]
14. Biological and molecular studies on specific immune cells treated with checkpoint inhibitors for the thera-personal approach of breast cancer patients (
El-Houseini ME; Arafat MS; El-Husseiny AM; Kasem IM; Kamel MM; El-Habashy AH; Khafagy MM; Radwan EM; Helal MH; Abdellateif MS
Oncol Res; 2021; 29(5):319-330. PubMed ID: 37305162
[TBL] [Abstract] [Full Text] [Related]
15. Pentoxifylline changes the balance of immune cell population in breast tumor-infiltrating lymphocytes.
Kazemi MH; Shokrollahi Barough M; Momeni-Varposhti Z; Ghanavatinejad A; Zarehzadeh Mehrabadi A; Sadeghi B; Falak R
Med Oncol; 2023 May; 40(6):168. PubMed ID: 37149505
[TBL] [Abstract] [Full Text] [Related]
16. An increase in tumor-infiltrating lymphocytes after treatment is significantly associated with a poor response to neoadjuvant endocrine therapy for estrogen receptor-positive/HER2-negative breast cancers.
Fukui R; Watanabe T; Morimoto K; Fujimoto Y; Nagahashi M; Ishikawa E; Hirota S; Miyoshi Y
Breast Cancer; 2023 Sep; 30(5):703-713. PubMed ID: 37115435
[TBL] [Abstract] [Full Text] [Related]
17. Vascular endothelial growth factor inhibitors promote antitumor responses via tumor microenvironment immunosuppression in advanced colorectal cancer.
Hamada Y; Tanoue K; Kita Y; Tanabe K; Hokonohara K; Wada M; Hozaka Y; Oi H; Nakayama C; Higashi M; Arigami T; Mori S; Ohtsuka T
Scand J Gastroenterol; 2023; 58(9):1009-1020. PubMed ID: 36987919
[TBL] [Abstract] [Full Text] [Related]
18. Depletion of Mannose Receptor-Positive Tumor-associated Macrophages via a Peptide-targeted Star-shaped Polyglutamate Inhibits breast cancer Progression in Mice.
Lepland A; Malfanti A; Haljasorg U; Asciutto EK; Pickholz M; Bringas M; Đorđević S; Salumäe L; Peterson P; Teesalu T; Vicent MJ; Scodeller P
Cancer Res Commun; 2022 Jun; 2(6):533-551. PubMed ID: 36923553
[TBL] [Abstract] [Full Text] [Related]
19. Programmed death ligand 1-positive immune cells in primary tumor or metastatic axillary lymph nodes can predict prognosis of triple-negative breast cancer even when present at < 1% in the tumor region.
Tomioka N; Hatanaka KC; Okuyama D; Watanabe KI; Yamamoto M; Maeda H; Tachikawa H; Kuwahara S; Shimizu A; Suzuki H; Hatanaka Y; Takahashi M
Breast Cancer; 2023 May; 30(3):497-505. PubMed ID: 36892732
[TBL] [Abstract] [Full Text] [Related]
20. TNFR2 expression predicts the responses to immune checkpoint inhibitor treatments.
Liao P; Jiang M; Islam MS; Wang Y; Chen X
Front Immunol; 2023; 14():1097090. PubMed ID: 36865537
[TBL] [Abstract] [Full Text] [Related]
[Next]
